|
1）Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51
|
|
|
|
2）Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121: 4393-408
|
|
|
|
|
|
3）Kawaguchi H, Manabe N, Miyaura C, et al. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest. 1999; 104: 229-37
|
|
|
|
|
|
4）Suga T, Kurabayashi M, Sando Y, et al. Disruption of the klotho gene causes pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am J Respir Cell Mol Biol. 2000; 22: 26-33
|
|
|
|
|
|
5）Nagai T, Yamada K, Kim HC, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003; 17: 50-2
|
|
|
|
|
|
6）Kamemori M, Ohyama Y, Kurabayashi M, et al. Expression of Klotho protein in the inner ear. Hear Res. 2002; 171: 103-10
|
|
|
|
|
|
7）White KE, Evans WE, O’Rlordan JLH, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26: 345-8
|
|
|
|
|
|
8）Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35
|
|
|
|
|
|
9）White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001; 60: 2079-86
|
|
|
|
|
|
10）Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8
|
|
|
|
|
|
11）Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281: 15694-700
|
|
|
|
|
|
12）Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281: 6120-3
|
|
|
|
|
|
13）Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444: 770-4
|
|
|
|
|
|
14）Hu MC, Shiizaki K, Kuro-o M, et al. Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013; 75: 503-33
|
|
|
|
|
|
15）Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013; 9: 650-60
|
|
|
|
|
|
16）Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-8
|
|
|
|
|
|
17）Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-33
|
|
|
|
|
|
18）Kuro-o M. A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech Ageing Dev. 2010; 131: 270-5
|
|
|
|
|
|
19）Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis. 2013; 62: 339-51
|
|
|
|
|
|
20）Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol. 2013; 180: 47-63
|
|
|
|
|
|
21）Okawa A, Nakamura I, Goto S, et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998; 19: 271-3
|
|
|
|
|
|
22）Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet. 2003; 34: 379-81
|
|
|
|
|
|
23）Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386: 78-81
|
|
|
|
|
|
24）Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003; 112: 357-66
|
|
|
|
|
|
25）Matsui I, Hamano T, Mikami S, et al. Retention of fetuin-A in renal tubular lumen protects the kidney from nephrocalcinosis in rats. Am J Physiol Renal Physiol. 2013; 304: F751-60
|
|
|
|
|
|
26）Heiss A, Pipich V, Jahnen-Dechent W, et al. Fetuin-A is a mineral carrier protein: small angle neutron scattering provides new insight on fetuin-a controlled calcification inhibition. Biophys J. 2010; 99: 3986-95
|
|
|
|
|
|
27）Hamano T, Matsui I, Mikami S, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010; 21: 1998-2007
|
|
|
|
|
|
28）Smith ER, Ford ML, Tomlinson LA, et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012; 27: 1957-66
|
|
|
|
|
|
29）Chmielewski M, Carrero JJ, Stenvinkel P, et al. Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol. 2009; 20: 3-9
|
|
|
|
|
|
30）Hruska KA, Choi ET, Memon I, et al. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol. 2010; 25: 769-78
|
|
|
|
|
|
31）Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001; 89: 1147-54
|
|
|
|
|
|
32）Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10-7
|
|
|
|
|
|
33）Sage AP, Lu J, Tintut Y, et al. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-22
|
|
|
|
|
|
34）Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol. 2009; 29: 761-6
|
|
|
|
|
|
35）Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008; 103: e28-34
|
|
|
|
|
|
36）Smith ER, Hanssen E, McMahon LP, et al. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One. 2013; 8: e60904
|
|
|
|
|
|
37）Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011; 10: 319-29
|
|
|
|
|
|
38）O’Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013; 493: 346-55
|
|
|
|
|
|
39）Garinis GA, van der Horst GT, Vijg J, et al. DNA damage and ageing: new-age ideas for an age-old problem. Nat Cell Biol. 2008; 10: 1241-7
|
|
|
|
|
|
40）Vijg J. The role of DNA damage and repair in aging: new approaches to an old problem. Mech Ageing Dev. 2008; 129: 498-502
|
|
|
|
|
|
41）Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner’s syndrome gene [see comments]. Science. 1996; 272: 258-62
|
|
|
|
|
|
42）Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998; 281: 1677-9
|
|
|
|
|
|
43）Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell. 2004; 14: 501-13
|
|
|
|
|
|
44）Jurk D, Wilson C, Passos JF, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun. 2014; 2: 4172
|
|
|
|
|
|
45）Niedernhofer LJ, Garinis GA, Raams A, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature. 2006; 444: 1038-43
|
|
|
|
|
|
46）van der Pluijm I, Garinis GA, Brandt RM, et al. Impaired genome maintenance suppresses the growth hormone--insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol. 2007; 5: e2
|
|
|
|
|
|
47）Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology. 2005; 146: 3718-23
|
|
|
|
|
|
48）Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005; 120: 449-60
|
|
|
|
|
|
49）Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325: 201-4
|
|
|
|
|
|
50）Spindler SR. Caloric restriction: from soup to nuts. Ageing Res Rev. 2010; 9: 324-53
|
|
|
|
|
|
51）Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One. 2011; 6: e18398
|
|
|
|
|
|
52）Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012; 26: 312-24
|
|
|
|
|
|
53）Ogawa Y, Kurosu H, Yamamoto M, et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A. 2007; 104: 7432-7
|
|
|
|
|
|
54）Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013; 19: 1147-52
|
|
|
|
|
|
55）Inagaki T, Lin VY, Goetz R, et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008; 8: 77-83
|
|
|
|
|
|
56）Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 2009; 106: 10853-8
|
|
|
|
|
|
57）Zhang Y, Xie Y, Berglund ED, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife. 2012; 1: e00065
|
|
|
|
|
|
58）Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007; 5: 415-25
|
|
|
|
|